News
-
-
PRESS RELEASE
Crossject confirms ZEPIZURE® supply chain readiness with another successful ISO audit for Quality Management System
Crossject confirms readiness of ZEPIZURE® supply chain after successful ISO 13485 audit for manufacturing sites in Dijon and Gray (France), preparing for commercialization in the U.S -
-
PRESS RELEASE
Crossject launches reserved capital increase and warrants issuance for an aggregate amount of at least €7m
Crossject launches reserved capital increase and warrants issuance for at least €7 million, engaging with investors through private placement. Transaction details disclosed for immediate new funding to support ZEPIZURE® development -
-
PRESS RELEASE
Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement
Crossject and the U.S. Department of Defense extend their cooperative research on needle-free autoinjectors, aiming to provide life-saving treatment in extreme conditions -
-
-
-